Cannabis for Older Adults With Hepatitis C: Safety and Dosing

Hepatic Metabolism and the Aging Liver

Physiological changes in the aging liver cannot be ignored. Hepatic volume and blood flow decrease by 35% to 40% in older adults, which alters how substances are cleared. Because cannabinoids are highly lipophilic (fat-soluble), they rely on the liver for processing.

The P-glycoprotein (P-gp) Efflux Transporter

One overlooked factor in drug-drug interactions is the P-glycoprotein efflux pump. This protein acts as a biological gatekeeper, pushing foreign substances out of cells. Research shows that both CBD and THC may inhibit P-gp activity. When this pump is inhibited, concurrent medications—specifically statins and certain anticoagulants—can accumulate in the bloodstream, reaching levels that may become toxic. For the HCV patient, liver safety hinges on understanding how these cannabinoids interact with their existing pharmaceutical regimen.

Targeted Terpene and Cannabinoid Interactions

Effective HCV symptom management should address secondary complications common in this cohort: arthralgia, cognitive fatigue, and sarcopenia.

Beta-Caryophyllene for Systemic Inflammation

HCV often causes systemic inflammation and joint pain (arthralgia). Beta-Caryophyllene, a sesquiterpene found in black pepper and cannabis, acts as a selective CB2 receptor agonist. By modulating the immune response without directly activating CB1 receptors in the central nervous system, it may provide anti-inflammatory relief without the cognitive impairment often associated with high-THC products.

THCV and Cognitive Fatigue

Many patients experience "brain fog" even after viral clearance. Low-dose Tetrahydrocannabivarin (THCV) acts as a neutral CB1 antagonist. When used in small concentrations, it provides a stimulating effect that may help counteract HCV-related lethargy, while avoiding the memory impairment risks standard THC poses to the aging brain.

Limonene and Phase II Detoxification

Limonene is a monoterpene that may support liver function by inducing Phase II detoxification enzymes. Strains dominant in Limonene are often preferred for patients managing the depressive side effects of long-term liver disease, as they may offer an uplifting shift in mood.

Bioavailability and Liver Strain: Delivery Methods Matter

The method of delivery changes the "first-pass metabolism" the liver must endure.

• Transdermal Patches: These offer a high safety profile for HCV patients. By delivering cannabinoids through the dermis, they bypass the liver, providing steady 12-hour titration without adding to the liver's workload.
• Sublingual Tinctures: These are absorbed via the oral mucosa, bypassing much of the first-pass metabolism and putting less pressure on hepatic enzymes than oral ingestion.
• Oral Edibles: These present the highest liver strain. The liver must convert Delta-9-THC into 11-Hydroxy-THC, a process that is unpredictable in a compromised liver, often leading to intense psychoactivity.
• Inhalation: While this bypasses the liver, it poses respiratory risks for seniors and causes rapid spikes in plasma levels, which increases the risk of orthostatic hypotension and falls.

The CYP450 Enzyme Pathway and Drug Interactions

The liver uses the Cytochrome P450 (CYP450) enzyme system to process many pharmaceuticals.

Competition for CYP3A4 and CYP2C19

CBD is a potent inhibitor of CYP3A4 and CYP2C19. Because many DAAs and common senior prescriptions (like Warfarin) rely on these same pathways, high doses of CBD may cause these medications to stay in the system longer than intended. This increases the risk of side effects or may alter the efficacy of the antiviral treatment. A simple rule of thumb: if a medication has a "grapefruit warning," it likely interacts with CBD.

Dosing Protocols for Compromised Hepatic Function

Because the geriatric liver processes compounds more slowly, dose accumulation is a clinical risk.

1. The 2.5mg Threshold: Start low—a maximum of 2.5mg of cannabinoids is a common entry point.
2. The 72-Hour Observation: Watch for a "metabolic hangover." If the patient feels groggy the following morning, the liver may not have cleared the previous dose.
3. Hydration Requirements: Hepatic processing is water-intensive. Patients should drink 8oz of water per dose to assist metabolic clearance.
4. Strain Selection: Stick to chemotypes with at least a 5:1 CBD to THC ratio. This maximizes the entourage effect while minimizing the risk of THC-induced confusion or falls.

Senior-Specific Cannabinoid Profiles

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

2. Bifulco M, Grimaldi C, Laezza C, Marasco G. (2006). Cannabinoids and hepatitis C: mechanisms of action and therapeutic relevance. Gut. 55(1):1-3. PubMed

3. Khatri UG, Silverstein SM, Chorba T. (2020). Baby boomers and hepatitis C: a public health perspective on testing and linkage to care. Am J Public Health. 110(2):153-155. PubMed

4. Pertwee RG. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 153(2):199-215. PubMed